Research material and lot documents
KLOW peptide benefits have not been established for the specified four-component blend by the studies cited here. Those papers tested individual components or a two-component combination.
KLOW peptide components and amounts identifies the supplier formulation.
On October 14, 2026, the exact-name AND searches for GHK-Cu, BPC-157, TB-500 and KPV returned zero PubMed records and zero ClinicalTrials.gov records. Sources: Dated four-component PubMed search and Dated four-component ClinicalTrials.gov search.
A broader KLOW-and-peptide PubMed search returned seven unrelated records, including author-name and biochemical-term matches. The exact KLOW registry search returned one unrelated education record with a typo. Sources: PubMed KLOW and peptide name search and ClinicalTrials.gov exact KLOW search. No direct specified blend study was located; these name-based searches can miss work under other terms or outside the databases.
In the 1993 rat wound-chamber experiment, the authors reported increased collagen and glycosaminoglycan content and extracellular-matrix accumulation with GHK-Cu. Source: 1993 GHK-Cu rat wound-chamber study, PMID 8227353.
The 2011 study used rat Achilles tendon explants and cultured tendon fibroblasts. The authors reported:
Greater tendon-explant outgrowth.
Greater fibroblast migration and survival under oxidative stress.
No direct effect on fibroblast proliferation in the assay.
Source: 2011 BPC-157 rat tendon-cell study, PMID 21030672.
The 2012 analytical paper used chromatography and mass spectrometry to identify Ac-LKKTETQ in a product sold as TB-500. The authors characterized a material's identity. Source: 2012 TB-500 analytical identity study, PMID 22962027.
The 2008 paper used human-derived intestinal epithelial and Jurkat cells and chemically induced mouse colitis. The authors investigated PepT1-mediated KPV uptake and reported reduced inflammatory measures. Source: 2008 KPV cell and mouse study, PMID 18061177.
These findings concern each study's material and model. Human-derived cells in culture are not a clinical trial in people, and none of these experiments tests the complete KLOW formulation.
In the exploratory 2026 rat Achilles tendon study, the authors compared BPC-157, a material called synthetic thymosin beta-4 (TB-500), and their pair. They reported no added benefit for the combination. GHK-Cu and KPV were absent. Source: 2026 BPC-157 and TB-500 rat study, PMID 42542926.
The abstract leaves the TB-500 full-length/fragment identity unresolved against FDA TB-500 fragment identity record. The result applies to that experiment and cannot decide KLOW's effect. The KLOW vs GLOW vs Wolverine comparison gives the related formulation and packaging differences.
FDA's component information, dated April 22, 2026, describes insufficient human safety information for BPC-157 and no identified human exposure data for KPV and the thymosin beta-4 fragment. Source: FDA component safety information, content dated April 22, 2026. Those component statements and the experimental studies above do not establish a human safety profile or adverse-event frequencies for KLOW.
Identify whether the paper tested a component, a pair or the complete formulation.
Keep the measured endpoint and study model attached to the finding.
Check the exact molecular identity, including the TB-500 fragment question.
Read the negative findings as well as the positive ones.
Research material: the KLOW 80 mg kit at Curo and Curo's lot certificates.
For the material documents, read KLOW research-material and lot-document checks.